PDL BioPharma Gross Profit 2010-2020 | PDLI
PDL BioPharma gross profit from 2010 to 2020. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
PDL BioPharma Annual Gross Profit
(Millions of US $) |
| 2020 |
$ |
| 2019 |
$1 |
| 2018 |
$150 |
| 2017 |
$290 |
| 2016 |
$240 |
| 2015 |
$590 |
| 2014 |
$581 |
| 2013 |
$456 |
| 2012 |
$381 |
| 2011 |
$362 |
| 2010 |
$345 |
| 2009 |
$318 |
PDL BioPharma Quarterly Gross Profit
(Millions of US $) |
| 2020-12-31 |
|
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$-33 |
| 2019-09-30 |
$29 |
| 2019-06-30 |
$3 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$34 |
| 2018-09-30 |
$56 |
| 2018-06-30 |
$32 |
| 2018-03-31 |
$28 |
| 2017-12-31 |
$50 |
| 2017-09-30 |
$57 |
| 2017-06-30 |
$139 |
| 2017-03-31 |
$43 |
| 2016-12-31 |
$66 |
| 2016-09-30 |
$54 |
| 2016-06-30 |
$21 |
| 2016-03-31 |
$103 |
| 2015-12-31 |
$178 |
| 2015-09-30 |
$125 |
| 2015-06-30 |
$138 |
| 2015-03-31 |
$150 |
| 2014-12-31 |
$117 |
| 2014-09-30 |
$165 |
| 2014-06-30 |
$163 |
| 2014-03-31 |
$137 |
| 2013-12-31 |
$116 |
| 2013-09-30 |
$100 |
| 2013-06-30 |
$149 |
| 2013-03-31 |
$92 |
| 2012-12-31 |
$92 |
| 2012-09-30 |
$85 |
| 2012-06-30 |
$126 |
| 2012-03-31 |
$77 |
| 2011-12-31 |
$73 |
| 2011-09-30 |
$84 |
| 2011-06-30 |
$122 |
| 2011-03-31 |
$83 |
| 2010-12-31 |
$76 |
| 2010-09-30 |
$86 |
| 2010-06-30 |
$120 |
| 2010-03-31 |
$62 |
| 2009-12-31 |
$58 |
| 2009-09-30 |
$71 |
| 2009-06-30 |
$126 |
| 2009-03-31 |
$63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.055B |
|
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
|
